Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exact Sciences ( (EXAS) ) has provided an announcement.
On March 23, 2026, Exact Sciences became a wholly owned subsidiary of Abbott through a merger in which each Exact share was converted into the right to receive $105 in cash, with all common stockholders losing shareholder rights other than payment and the stock being halted and delisted from Nasdaq, with SEC deregistration steps initiated. As part of the transaction, all outstanding equity awards were vested, cancelled, or converted into cash or Abbott equity, the company’s board and officers resigned, its charter and bylaws were fully restated, its convertible notes’ conversion rights were modified to cash-based terms tied to the $105 price, and Exact fully repaid and terminated its existing credit facility, collectively marking a full change of control and capital structure simplification for stakeholders.
The most recent analyst rating on (EXAS) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.
Spark’s Take on EXAS Stock
According to Spark, TipRanks’ AI Analyst, EXAS is a Neutral.
The score is driven primarily by improving financial quality (notably strong recent cash flow and stable high gross margins) and a solid uptrend in technicals. These positives are tempered by continued net losses (negative P/E), meaningful leverage, and some remaining transaction-related legal risk as the Abbott deal approaches closing.
To see Spark’s full report on EXAS stock, click here.
More about Exact Sciences
Exact Sciences is a medical diagnostics company focused on cancer screening and related diagnostic tests, operating in the broader healthcare and life sciences industry. Its products and services target early detection and management of disease, positioning the firm as a key player in precision diagnostics for patients, providers, and payers in the U.S. market and beyond.
Average Trading Volume: 2,533,521
Technical Sentiment Signal: Buy
Current Market Cap: $20.03B
For a thorough assessment of EXAS stock, go to TipRanks’ Stock Analysis page.